Piramal Pharma Limited (PPL) announced the successful closure of the US Food and Drug Administration (FDA) inspection at its manufacturing facility located in Sellersville, USA. This follows a previous intimation on May 10th, 2026, regarding the inspection. The company has received an Establishment Inspection Report (EIR) from the US FDA, confirming the closure of the inspection. This positive development signifies regulatory compliance and operational efficiency at the Sellersville facility.
